Unidade Local De Saude Da Regiao De Aveiro E.P.E.

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease3 trials
• Myeloproliferative neoplasms3 trials
• Hypertrophic cardiomyopathy2 trials
• Obesity2 trials
• Type 2 diabetes2 trials
• Acute myeloid leukaemia1 trial
• COPD1 trial
• Coronary artery disease1 trial
• High blood pressure1 trial
• HIV1 trial
• Idiopathic pulmonary fibrosis1 trial
• IgA nephropathy1 trial
• and 4 more

Phase

• Phase 315 trials
• Phase 24 trials
• Phase 2/32 trials

Status

• Completed8 trials
• Recruiting7 trials
• Not yet recruiting4 trials
• Active, not recruiting2 trials

Lead sponsor

• Boehringer Ingelheim3 trials
• Cytokinetics2 trials
• Kartos Therapeutics Inc.2 trials
• Novo Nordisk A/S2 trials
• AbbVie1 trial
• and 11 more

Running trials

• Recruiting

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

  NCT07843472· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia older than 60 years and/or inelegible for standard induction chemotherapy

  2025-523238-17-00· Phase 2· Fundacion PETHEMA· Source

• Recruiting

  INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

  NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· ViiV Healthcare· Source

• Recruiting

  RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.

  2025-521802-17-00· Phase 3· Farmalider S.A.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

  NCT06486883· Phase 2· MedSIR· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Active, not recruiting

  Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

  NCT06806293· Phase 3· AbbVie· Source

• Recruiting

  Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis

  2023-504724-25-00· Phase 3· Kartos Therapeutics Inc.· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Enrolling by invitation

  Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

  NCT04848506· Phase 2/3· Cytokinetics· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Myeloproliferative neoplasms2 recruiting
• Acute myeloid leukaemia1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Metastatic breast cancer1 recruiting
• Obesity1 recruiting
• Osteoarthritis1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

  NCT05352815· Phase 3· Novo Nordisk A/S· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04751487· Phase 3· Sanofi· Source

• Active, not recruiting

  KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

  NCT03662126· Phase 2/3· Kartos Therapeutics Inc.· Source